Article type: Review Article
Article
title: The
ditans, a new class for acute migraine: minireview
Journal: Journal
of Current Research in Scientific Medicine
Year: 2020
Authors: Jamir Pitton Rissardo, Ana Letícia Fornari
Caprara
E-mail: jamirrissardo@gmail.com
ABSTRACT
Lasmiditan
(LDT), a new drug, was approved by the Food and Drug Administration in October
2019 for acute migraines with or without aura. LDT belongs to a new class of
drugs “-ditans,” in which the mechanism is different from the triptans since it
does not show vasoactive effects. The “-ditans” are more likely to be involved
with the trigeminal system without causing vasoconstriction because of its low
affinity for 5-HT1B receptors and highly selective 5-HT1F receptor agonist. The
LDT probably decreases the neurogenic inflammation of the dura by lowering
plasma protein extravasation and inhibits or suppresses neuronal firing in the
trigeminal nucleus caudalis. Moreover, 5HT1F agonists have shown to decrease
c-fos activity within the trigeminal nucleus, which reduces the level of
synaptic activation. The onset of action of LDT is fast, which shows rapid
absorption with good oral bioavailability. The peak plasma occurs within 2 h
and the distribution is half associated with proteins. The LDT metabolism is
hepatic but also nonhepatic by noncytochromes P450.
Key-words: 5-ht1f receptor agonist, lasmiditan, migraine, trigeminal ganglion, trigeminal nucleus caudalis
Full
text available at:
DOI
10.4103/jcrsm.jcrsm_45_19
Citation
Rissardo JP, Fornari Caprara AL. The ditans, a new class for acute migraine: minireview. J Curr Res Sci Med 2020;6:11-4
